Innovative therapeutics

Investors

NASDAQBMRN
FormDescriptionDateFormat
424B3Form of prospectus reflecting facts events constituting substantive change from last formDec 29, 2003View HTMLDownload DOCDownload PDFDownload XLS
424B3Form of prospectus reflecting facts events constituting substantive change from last formDec 18, 2003View HTMLDownload DOCDownload PDFDownload XLS
S-3/APre-effective amendment to an S-3 filingDec 5, 2003View HTMLDownload DOCDownload PDFDownload XLS
S-3Simplified registration formSep 22, 2003View HTMLDownload DOCDownload PDFDownload XLS
8-A12G/AAmendment to a previously filed 8-A12GAug 8, 2003View HTMLDownload DOCDownload PDFDownload XLS
424B2Form of prospectus filed in connection with primary offering of securities on a delayed basisApr 7, 2003View HTMLDownload DOCDownload PDF
424B2Form of prospectus filed in connection with primary offering of securities on a delayed basisMar 13, 2003View HTMLDownload DOCDownload PDF
424B2Form of prospectus filed in connection with primary offering of securities on a delayed basisFeb 27, 2003View HTMLDownload DOCDownload PDF
424B5Form of prospectus disclosing information facts events covered in both forms 424B2 424B3Feb 21, 2003View HTMLDownload DOCDownload PDFDownload XLS
424B5Form of prospectus disclosing information facts events covered in both forms 424B2 424B3Feb 5, 2003View HTMLDownload DOCDownload PDFDownload XLS
S-3/APre-effective amendment to an S-3 filingJan 17, 2003View HTMLDownload DOCDownload PDFDownload XLS

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information